Introduction
============

Low-grade gliomas (LGGs) include Grade II astrocytomas, oligodendrogliomas, and oligoastrocytomas.[@b1-ott-9-5117] Surgery is usually the first choice of treatment. It is as still unclear whether the best option for postoperative patients with LGGs is radiotherapy (RT) alone or chemoradiotherapy. A Phase III trial investigated differences in patients with LGGs, who underwent incomplete resection and subsequent RT with or without chemotherapy (procarbazine or lomustine \[CCNU\]), but no statistically significant differences were observed owing to its premature termination.[@b2-ott-9-5117] In another Phase III trial by the Radiation Therapy Oncology Group, RTOG 9802,[@b3-ott-9-5117] a categorical benefit in overall survival (OS) was seen in the procarbazine, lomustine, and vincristine (PCV) + RT arm compared with the RT-alone arm; however, the patients selected for this trial were not all of postoperative status and also included those who were \>40 years old and had undergone a subtotal resection.[@b3-ott-9-5117] This trial resulted in chemoradiotherapy being the standard treatment for high-risk LGG patients.

In recent times, temozolomide (TMZ) with its improved side effects has garnered much attention. TMZ is a second-generation alkylating agent with a low molecular mass. It has excellent oral bioavailability, attains peak plasma concentration in 1 hour, and easily penetrates the blood--brain barrier. In 2005, TMZ was considered as standard chemotherapy for glioblastoma treatment. Meanwhile, another trial, RTOG 0424, was initiated to identify the role of TMZ in conjunction with RT for postoperative LGGs. The recently published results showed that the 3-year OS rate of high-risk LGG patients who underwent TMZ chemotherapy plus RT was higher than that of the controls who only underwent RT.[@b4-ott-9-5117] However, the trial was a single-arm study that used historical controls for comparison. Our retrospective study was designed to investigate the role of TMZ in combination with RT for postoperative LGGs.

Patients and methods
====================

Patient selection
-----------------

Between June 2011 and December 2013, 83 patients with pathologically confirmed Grade II gliomas (including astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas) at the Shandong Cancer Hospital Affiliated to the Shandong University were retrospectively analyzed, but 14 patients were lost to follow-up. Thus, 69 patients were selected for the analysis. All patients were at least 18 years old at diagnosis. Besides surgery, no prior treatments were performed before radiation or chemoradiotherapy. Other diseases had to be evaluable. Patients with a history of other cancers who were in remission were excluded. [Table 1](#t1-ott-9-5117){ref-type="table"} lists the main characteristics of the enrolled patients: 31 patients in the concurrent TMZ chemoradiotherapy group (TMZ + RT), and 38 patients in the radiation alone group (RT-alone). There were no statistically significant differences in patient features or tumor characteristics between the two groups ([Table 1](#t1-ott-9-5117){ref-type="table"}). The study was approved by the ethics committee of the Shandong Cancer Prevention and Treatment Research who deemed patient consent was not required due to the retrospective nature of the study.

Radiotherapy
------------

RT was performed 2--4 weeks after surgery when the skin incision had almost healed. Patients were fixed with a thermal head mold and positioned under a computed tomography simulator. Radiation was delivered using a Varian linear accelerator (Varian Medical Systems, Palo Alto, CA, USA). The gross tumor volume was targeted on the contrast-enhancing residual tumor and/or surgical residual cavity of postoperative T2-weighted magnetic resonance imaging. The planning target volume was more than 2 cm margin to the dose of 50 Gy, and then the expanded margin was shrunk to 1 cm with a total dose ranging from 50 to 66 Gy in daily 2 Gy fractions by three-dimensional conformal radiation therapy.[@b5-ott-9-5117]--[@b7-ott-9-5117] Once symptoms of cerebral edema (such as headache, dizziness, or nausea) appeared during radiation, patients were given different doses of mannitol and dexamethasone by intravenous infusion based on the severity of symptoms.

Chemotherapy
------------

Patients undergoing chemotherapy provided written consent for concurrent oral administration of 50--100 mg TMZ every day until the RT regimen was completed. Myelosuppressive and digestive-symptom side effects were effectively relieved. TMZ administration was stopped if the disease progressed or unacceptable toxicity was observed. Fortunately, only two patients in group TMZ + RT (2/31) showed slight digestive symptoms during therapy, and myelosuppression was not observed in anybody. No patient required cessation of concurrent TMZ chemotherapy owing to intolerable toxicity.

Follow-up
---------

Follow-up was every 3 months in the first 2 years and then every 6 months thereafter. Each visit included physical examinations, magnetic resonance imaging of the brain, and other examinations according to symptoms (as necessary).

Statistical analysis
--------------------

The following definitions were used for statistical analyses: progression-free survival (PFS) was defined as the time from the date of surgery to the date of disease progression or latest follow-up; OS was defined as the time from the date of surgery to the date of death or latest follow-up.

Differences in patient demographics, tumors, and treatment were calculated using Student's *t*-test for numerical data and *χ*^2^ test or Fisher's exact test for categorical data. Kaplan--Meier survival curves were plotted, and the survival distributions between the two groups were compared using the log-rank test. The Cox regression analysis was used to assess the association between OS or PFS and prognostic factors. Two-sided *P*-values of \<0.05 were considered statistically significant. Statistical calculations were performed using SPSS version 17.0 statistical software (SPSS Inc., Chicago, IL, USA).

Results
=======

Of all enrolled patients, 12 (38.71%) and 17 (43.58%) patients were \>45 years in the TMZ + RT and RT-alone groups, respectively (*P*=0.61). More patients in the TMZ + RT group underwent a subtotal resection than those in the RT-alone group (29.03% vs 18.42%), but this difference was not statistically significant (*P*=0.30). The median follow-up after surgery was 33 months (range, 10--72 months) and was similar between the two groups (29 months for the TMZ + RT group and 35.5 months for RT-alone group; *P*=0.06). The overall 2-year PFS rate was 71.0% (83.9% for TMZ-RT group and 60.5% for RT-alone group). The subgroups showed statistically significant differences (*P*=0.037, [Figure 1](#f1-ott-9-5117){ref-type="fig"}). The overall 2-year OS rate was 89.86% ([Figure 2](#f2-ott-9-5117){ref-type="fig"}). The median survival time has not yet been reached.

We conducted a Cox regression analysis to study the association between OS or PFS and the following prognostic factors: chemotherapy (with TMZ), age, age distribution (≥45 years old and \<45 years old), sex, resection margin (complete or incomplete), radiation dose, and histology. Age distribution and resection margin were significantly associated with OS (*P*=0.03, hazard ratio \[HR\] =0.015, 95% confidence interval (CI): 0.00--0.65; *P*=0.004, HR =19.89, 95% CI: 2.65--149.29, respectively). The concurrent TMZ chemotherapy was significantly associated with PFS (*P*=0.046, HR =0.34, 95% CI: 0.12--0.98; [Table 2](#t2-ott-9-5117){ref-type="table"}).

Discussion
==========

The role of chemotherapy in patients with LGGs had not been clearly established until the results of the RTOG 9802 Phase III trial were published. Previously, recurrent or progressive LGGs treated with single agents such as nitrosourea or TMZ or with combined chemotherapy such as CCNU and PCV showed encouraging responses,[@b8-ott-9-5117]--[@b14-ott-9-5117] but no convincing OS benefit.[@b13-ott-9-5117],[@b15-ott-9-5117] Then, the results of the RTOG 9802 trial[@b3-ott-9-5117] showed significant improvements in PFS among patients treated with PCV + RT. On account of its easy administration and a favorable quality-of-life profile,[@b16-ott-9-5117] TMZ has been studied more extensively in recent years. A few trials have demonstrated its efficacy by analyzing recurrent Grade II and III gliomas.[@b8-ott-9-5117],[@b10-ott-9-5117] Some researchers report that chemotherapy could have been used to decrease the postoperative tumor volume for patients who underwent a subtotal resection, which was aimed at achieving a better prognosis.[@b17-ott-9-5117]--[@b19-ott-9-5117] The RTOG 0424 trial[@b4-ott-9-5117] focused on the survival benefit for postoperative patients treated with TMZ + RT compared with RT alone. However, patients in this randomized trial were required to have three or more risk factors for recurrence. Compared with the historical controls, patients showed a significantly improved 3-year OS rate (54% vs 73.1%; *P*\<0.001). The 3-year PFS rate was 59.2%. Despite not having such a long follow-up, an improved 2-year PFS rate of 83.9% (*P*=0.037) and 2-year OS rate of 90.3% (*P*=0.861) was recorded in our study. The reason for the insignificant 2-year OS rate may be attributed to the inclusion of patients with risk factors for recurrence in the RTOG 0424 trial, while our study excluded such patients. Furthermore, few patients in the TMZ + RT group selected TMZ as an adjuvant chemotherapy. However, all patients included in the RTOG 0424 trial were administered TMZ as the adjuvant chemotherapy. Moreover, as mentioned, TMZ was also found beneficial for recurrent gliomas.[@b8-ott-9-5117],[@b10-ott-9-5117] Once progression or recurrence was diagnosed, patients in both groups of our study would have gone on with continued therapies, with TMZ included. While these factors could collectively result in less obvious survival advantages, improvements in PFS and OS appear favorable.

On the other hand, prognosis factors identified by Pignatti et al[@b20-ott-9-5117] were also included in the RTOG 0424 trial, and these were as follows: age ≥40 years, astrocytoma histology, bihemispheric tumor, preoperative tumor diameter of ≥6 cm, or a preoperative neurological function status of \>1. Histology was the only factor significantly associated with OS (*P*=0.027) and PFS (*P*=0.034). Other reports also showed that the prognosis of oligodendrogliomas was better than astrocytomas of the same grade, with mixed gliomas featuring somewhere in between.[@b20-ott-9-5117]--[@b22-ott-9-5117] However, histology did not show a significant association with either OS or PFS in our study. Meanwhile, we found that age distribution was also a related factor of OS (*P*=0.03), but not of PFS (*P*=0.34). The result should be viewed with the following considerations: 1) while patients in the RTOG 0424 trial underwent a subtotal resection, it was not considered a prognostic factor for OS; however, this was an important factor for OS (*P*=0.004) in our study; 2) all patients in the RTOG 0424 trial had high-risk LGGs, including those ≥40 years old; and 3) both our sample size and follow-up duration were comparatively shorter.

A growing number of studies have supported the role of surgical resection.[@b23-ott-9-5117]--[@b25-ott-9-5117] After Jakola et al[@b26-ott-9-5117] reported the comparison between surgery and biopsy, surgery became the first treatment choice for LGGs. No randomized trials examined the effect of the extent of surgical resection on PFS and OS, but its importance has been stressed by many recently published articles. A study with 170 patients with LGGs undergoing surgery showed a 95% 5-year OS rate with almost total removal compared with 70% with the subtotal removal.[@b27-ott-9-5117] Similarly, a study of 216 patients also found that the extent of resection was significantly related to OS: a 5-year OS rate of 76% associated with \<90% resection as compared with a 5-year OS rate of 97% associated with \>90% resection.[@b28-ott-9-5117] On the other hand, some studies show that although maximized surgery predicted improved OS in a univariate analysis, this association was lost when data were controlled for other prognostic factors.[@b20-ott-9-5117] Our study found statistically significant differences in total and subtotal resection subgroups by using both univariate (*P*=0.001) and multivariate analyses (*P*=0.004).

In terms of radiation, no advantages for higher vs lower doses were seen,[@b5-ott-9-5117],[@b6-ott-9-5117] although a better survival for doses greater than 50 Gy has been reported.[@b7-ott-9-5117] Most patients in our study were administered a dose \>50 Gy, except for seven patients who received exactly 50 Gy. Radiation dose was not related to either OS or PFS.

Conclusion
==========

Concurrent TMZ chemoradiotherapy with better tolerability may be beneficial for postoperative patients with LGGs. In addition, age distribution and surgical margin could be used to indicate prognosis. Further studies are necessary to expand the reach of our observations and clarify the links between prognostic factors and long-term survival.
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###### 

Patient characteristics for postoperative patients with LGG treated with concurrent TMZ + RT vs RT-alone (n=69)

  Characteristic value   TMZ + RT   RT-alone   Total    *P*-value
  ---------------------- ---------- ---------- -------- -----------
  Numbers of patient     31         38         69       
  Age (years)                                           0.33
   Median                41         43         43       
   Range                 18--62     24--63     18--63   
  Age distribution                                      0.61
   ≥45 years             12         17         29       
   \<45 years            19         21         40       
  Sex                                                   0.65
   Male                  18         20         38       
   Female                13         18         31       
  Resection margin                                      0.30
   Total                 22         31         53       
   Subtotal              9          7          16       
  Histopathology                                        0.32
   Astrocytomas          17         27         44       
   Oligodendrogliomas    6          6          12       
   Oligoastrocytomas     8          5          13       
  Time span (days)                                      0.86
   Mean                  17         18                  
   Range                 14--28     16--25              
  RT dose (Gy)                                          0.10
   Median                60         60         60       
   Range                 50--66     50--66     50--66   

**Notes:** Resection margin: complete resection or incomplete, time span: from surgery to the start of radiotherapy.

**Abbreviations:** LGGs, low-grade gliomas; TMZ, temozolomide; RT, radiotherapy.

###### 

Association between PFS or OS and the prognostic factors for postoperative patients with LGGs treated with TMZ + RT or RT-alone (n=69)

  Prognostic factors   *P*-value HR (95% CI)      
  -------------------- -------------------------- -----------------------------
  Sex                  0.58 (0.76, 0.29--1.98)    0.21 (0.28, 0.04--2.06)
  Age                  0.52 (0.98, 0.90--1.05)    0.44 (0.94, 0.81--1.10)
  Age distribution     0.39 (0.47, 0.08--2.62)    0.03 (0.015, 0.00--0.65)
  Resection margin     0.22 (1.95, 0.68--5.58)    0.004 (19.89, 2.65--149.29)
  Radiation dose       0.40 (1.06, 0.93--1.21)    0.30 (1.21, 0.84--1.74)
  Histology            0.83 (0.92, 0.44--1.93)    0.67 (0.72, 0.16--3.23)
  Chemotherapy         0.046 (0.34, 0.12--0.98)   0.375 (0.45, 2.65--149.3)

**Notes:** Age distribution: ≥45 years old or not, resection margin: complete resection or incomplete, chemotherapy: with TMZ or not.

**Abbreviations:** LGGs, low-grade gliomas; TMZ, temozolomide; RT, radiotherapy; OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval.
